Our results clarified a new mechanism which PRMT5 knockdown in cervical cancer cells drives an antitumor function via reprogramming T cell-mediated response and regulating PD-L1 expression, and indicated PRMT5 inhibitor could be a potential therapeutic strategy in cervical cancer. Here, CD274 is linked to cervical cancer.